A 32-year-old man from Delhi presents with a 4-month history of productive cough, fever, and night sweats. He had completed a standard 6-month anti-TB regimen (HRZE) 8 months ago for drug-susceptible TB. Chest X-ray shows bilateral upper lobe infiltrates with cavitation. Sputum smear microscopy is positive for acid-fast bacilli. Gene Xpert MTB/RIF assay shows MTB detected with RIF resistance. He denies any history of non-adherence. What is the most likely diagnosis?

Explanation

## Clinical Presentation & Diagnostic Reasoning This patient presents with: - **Prior TB treatment:** Completed standard 6-month HRZE regimen 8 months ago - **Current symptoms:** Recurrent cough, fever, night sweats after treatment completion - **Microbiological evidence:** Sputum smear positive, Gene Xpert MTB/RIF shows RIF resistance - **Radiological findings:** Bilateral upper lobe cavitary disease (typical TB pattern) ## Definition of MDR-TB **Key Point:** MDR-TB is defined as TB caused by *Mycobacterium tuberculosis* resistant to **at least isoniazid (INH) and rifampicin (RIF)** — the two most potent first-line drugs [cite:WHO TB Guidelines 2023]. Since this patient's isolate shows RIF resistance on Gene Xpert MTB/RIF, and given the prior treatment with HRZE (which includes INH), the isolate is almost certainly resistant to both INH and RIF, meeting the definition of MDR-TB. ## Why This Is Not Relapse of Drug-Susceptible TB **Clinical Pearl:** Relapse occurs when a patient reactivates the *same* susceptible strain after successful treatment. The appearance of RIF resistance indicates either: 1. **Acquired resistance** during the prior treatment course (usually due to non-adherence or malabsorption) 2. **Reinfection** with a resistant strain Either way, the current isolate is now resistant — this is MDR-TB, not drug-susceptible TB. ## Why This Is Not XDR-TB **High-Yield:** XDR-TB requires: - MDR-TB (INH + RIF resistance) **PLUS** - Resistance to **any fluoroquinolone** (e.g., levofloxacin) **AND** - Resistance to **at least one second-line injectable** (e.g., amikacin, capreomycin, streptomycin) The vignette provides no evidence of fluoroquinolone or injectable drug resistance. XDR-TB is a subset of MDR-TB with additional resistance; we cannot diagnose it without documented fluoroquinolone and injectable resistance. ## Why Non-Tuberculous Mycobacteria (NTM) Is Unlikely Gene Xpert MTB/RIF specifically detects *Mycobacterium tuberculosis* complex and reports RIF resistance. NTM would not be detected by this assay in the same way, and the clinical and radiological picture is classic for TB, not NTM lung disease. ## Summary Table: TB Resistance Definitions | **Resistance Pattern** | **Definition** | **Drugs Resistant To** | | --- | --- | --- | | **Drug-susceptible TB** | Susceptible to all first-line drugs | None | | **MDR-TB** | Resistant to INH + RIF | At minimum: INH, RIF | | **XDR-TB** | MDR-TB + FQ + injectable resistance | INH, RIF, FQ (any), + ≥1 injectable | | **Pre-XDR-TB** | MDR-TB + either FQ or injectable resistance | INH, RIF, + FQ OR injectable (not both) | ## Management Implications **Key Point:** MDR-TB requires a longer, more complex regimen (typically 20 months) using second-line drugs such as fluoroquinolones, bedaquiline, linezolid, and/or injectables, depending on susceptibility pattern and drug availability [cite:WHO TB Guidelines 2023].